Annual report pursuant to Section 13 and 15(d)

Royalty Purchase Agreements - Agenus (Details)

v3.20.1
Royalty Purchase Agreements - Agenus (Details)
$ in Thousands
 12 Months Ended
Sep. 20, 2018
USD ($)
product
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Agreements      
Payments to acquire milestones and royalties   $ 19,300 $ 15,000
Proceeds from issuance of long-term debt   9,500 7,500
Long-term royalty receivables   34,375 $ 15,000
Royalty Purchase Agreement | Agenus      
Agreements      
Payments to acquire milestones and royalties $ 15,000    
Long-term royalty receivables   $ 15,000  
Royalty Purchase Agreement | Agenus | Silicon Valley Bank Loan Agreement      
Agreements      
Proceeds from issuance of long-term debt $ 7,500    
Royalty Purchase Agreement | Agenus | Incyte Immuno-Oncology Assets      
Agreements      
Royalties on net sales of products (as a percent) 33.00%    
Number of licensed products related to milestone and royalties | product 6    
Purchased percentage of milestones 10.00%    
Royalty Purchase Agreement | Agenus | Merck Immuno-Oncology Product      
Agreements      
Royalties on net sales of products (as a percent) 33.00%    
Purchased percentage of milestones 10.00%    
Purchased eligible milestone payments receivable upon achievement of potential development, regulatory and commercial milestones $ 59,500